ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 170 filers reported holding ASCENDIS PHARMA A/S in Q3 2021. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $932,000 | -65.8% | 7,939 | -61.6% | 0.01% | -26.7% |
| Q2 2021 | $2,723,000 | +171.5% | 20,699 | +218.4% | 0.02% | +25.0% |
| Q3 2020 | $1,003,000 | +1.4% | 6,500 | -2.8% | 0.01% | +9.1% |
| Q2 2020 | $989,000 | -21.9% | 6,690 | -26.5% | 0.01% | +10.0% |
| Q4 2019 | $1,266,000 | +227.1% | 9,100 | +126.3% | 0.01% | +233.3% |
| Q3 2019 | $387,000 | -79.3% | 4,022 | -75.2% | 0.00% | -83.3% |
| Q2 2019 | $1,869,000 | -15.1% | 16,232 | -70.5% | 0.02% | +63.6% |
| Q4 2017 | $2,201,000 | -78.6% | 54,952 | -80.6% | 0.01% | -75.6% |
| Q3 2017 | $10,271,000 | +509.9% | 283,330 | +240.5% | 0.04% | +181.2% |
| Q4 2016 | $1,684,000 | – | 83,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |